REGENXBIO director granted RSUs and stock options

REGENXBIO Inc. director Daniel Tasse reported new equity awards.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

REGENXBIO Inc. director Daniel Tasse reported new equity awards. He received 9,807 shares of common stock through a time-based restricted stock unit grant, which will vest in full on May 29, 2027 if he remains in continuous service.

He was also granted stock options for 46,600 shares of common stock at an exercise price of $7.01 per share, vesting on May 29, 2027 and expiring on May 29, 2036. Following these awards, he directly holds 28,861 shares of common stock. These are compensation-related grants, not open-market purchases or sales.

Insider Trade Summary

Grant/Award: 56,407 shares

Grant/Award 2 txns

Insider Tasse Daniel

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (Right to Buy)	46,600	$0.00	$0.00
Grant/Award	Common Stock	9,807	$0.00	$0.00

Holdings After Transaction: Stock Options (Right to Buy) — 46,600 contracts (Direct); Common Stock — 28,861 shares (Direct)

Footnotes (2)

F1. Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 29, 2027 subject to the continuous service of the recipient to the Issuer.
F2. The option will vest on May 29, 2027 subject to the continuous service of the optionee to the Issuer.

Key Figures

RSU shares granted: 9,807 shares Common shares after grant: 28,861 shares Stock options granted: 46,600 options +3 more

6 metrics

RSU shares granted 9,807 shares Time-based RSU award vesting May 29, 2027

Common shares after grant 28,861 shares Direct holdings following RSU award

Stock options granted 46,600 options Right to buy REGENXBIO common stock

Option exercise price $7.01 per share Strike price for 46,600 options

Vesting date May 29, 2027 Vesting for RSUs and options

Option expiration May 29, 2036 Expiration date of granted options

Key Terms

restricted stock unit, Stock Options (Right to Buy), continuous service, time-based

4 terms

restricted stock unit financial

"Represents shares of common stock underlying a time-based restricted stock unit award (RSU)."

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

Stock Options (Right to Buy) financial

"Stock Options (Right to Buy) with an exercise price of 7.0100."

continuous service financial

"subject to the continuous service of the recipient to the Issuer."

time-based financial

"Represents shares of common stock underlying a time-based restricted stock unit award (RSU)."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did REGENXBIO (RGNX) director Daniel Tasse report in this Form 4?

Daniel Tasse reported receiving equity awards from REGENXBIO as director compensation. The filing shows grants of time-based restricted stock units and stock options, increasing his direct holdings without any open-market share purchases or sales.

How many REGENXBIO shares did Daniel Tasse receive through RSUs?

He received 9,807 shares of REGENXBIO common stock via a restricted stock unit grant. All 9,807 RSU shares will vest together on May 29, 2027, provided he continues serving the company through that date.

What stock options did REGENXBIO grant to director Daniel Tasse?

He was granted options covering 46,600 shares of REGENXBIO common stock. These options have a strike price of $7.01 per share, vest on May 29, 2027, and expire on May 29, 2036, subject to his continued service.

When do Daniel Tasse’s REGENXBIO RSUs and options vest?

Both the restricted stock units and stock options vest on May 29, 2027. Vesting is conditioned on Tasse’s continuous service to REGENXBIO through that date, as described in the Form 4 footnotes.

How many REGENXBIO common shares does Daniel Tasse hold after these grants?

After the RSU grant, Tasse directly holds 28,861 shares of REGENXBIO common stock. In addition, he now holds options giving him the right to buy 46,600 more shares at $7.01 per share if he chooses to exercise them.

Did Daniel Tasse buy or sell REGENXBIO shares on the market in this Form 4?

No, the Form 4 only shows compensation-related grants, not market trades. The RSU and option awards increased his equity exposure, but there were no open-market purchases or sales reported in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/02/2026 - 05:21 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tasse Daniel

(Last)

(First)

(Middle)

C/O REGENXBIO INC.

9804 MEDICAL CENTER DRIVE

(Street)

ROCKVILLE

MARYLAND

20850

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
REGENXBIO Inc. [ RGNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/29/2026		A		9,807⁽¹⁾	A	$0.00	28,861	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Options (Right to Buy)	$7.01	05/29/2026		A		46,600		05/29/2027⁽²⁾	05/29/2036	Common Stock	46,600	$0.00	46,600	D

Explanation of Responses:

1. Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 29, 2027 subject to the continuous service of the recipient to the Issuer.

2. The option will vest on May 29, 2027 subject to the continuous service of the optionee to the Issuer.

Remarks:

	/s/ Patrick J. Christmas as attorney-in-fact	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR